Multiple antigenic polypeptide composed of heparanase B‑cell epitopes shrinks human hepatocellular carcinoma in mice

Zhang,Jun; Yang,Jianmin; Cai,Yuan; Jin,Ni; Wang,Huiju; Yu,Tong

doi:10.3892/or.2014.3679

Multiple antigenic polypeptide composed of heparanase B‑cell epitopes shrinks human hepatocellular carcinoma in mice

Authors:
- Jun Zhang
- Jianmin Yang
- Yuan Cai
- Ni Jin
- Huiju Wang
- Tong Yu
View Affiliations

Affiliations: Department of Gastroenterology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Department of Gastroenterology, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang 310016, P.R. China, Department of Intensive Care Medicine, The Central Hospital of Jinhua City, Jinhua, Zhejiang 321001, P.R. China
Published online on: December 18, 2014 https://doi.org/10.3892/or.2014.3679
Pages: 1248-1256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to evaluate the anti‑growth effect of the self‑designed multiple antigenic polypeptide (MAP) vaccine comprising B‑cell epitopes of heparanase (HPSE) on HCC97‑H hepatocellular carcinoma (HCC) in mice. The polyclonal antibodies against the B‑cell epitopes of HPSE were prepared by immunizing rabbits with freshly synthesized MAP vaccine. HCC‑bearing models were constructed on BALB/c nude mice. Anti‑MAP antibodies were administrered to the models to assess the effects on HPSE activity, HCC growth, the expression of VEGF/bFGF and the value of micro‑vessel density (MVD). The anti‑MAP antibodies were harvested, purified and identified. These antibodies were able to specifically bind with the dominant epitopes of the precursor protein and large subunit monomer of HPSE, decrease HPSE activity, suppress the expressions of VEGF and bFGF, reduce the MVD, and markedly shrink the HCC volume. Based on these findings, MAP vaccine based on the B‑cell epitopes of HPSE seemed to provide theoretical evidence for further study of the synthesized HPSE MAP vaccine in the treatment of HCC.

View Figures

View References

1	Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312–1327. 2008. View Article : Google Scholar : PubMed/NCBI
2	Rabinovich GA, Gabrilovich D and Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar
3	Ostrand-Rosenberg S: Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev. 18:11–18. 2008. View Article : Google Scholar : PubMed/NCBI
4	Borghaei H, Smith MR and Campbell KS: Immunotherapy of cancer. Eur J Pharmacol. 625:41–54. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zarour HM and Ferrone S: Cancer immunotherapy: Progress and challenges in the clinical setting. Eur J Immunol. 41:1510–1515. 2011. View Article : Google Scholar : PubMed/NCBI
6	Van der Burg SH, Bijker MS, Welters MJ, et al: Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev. 58:916–930. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bijker MS, Melief CJ, Offringa R and van der Burg SH: Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 6:591–603. 2007. View Article : Google Scholar : PubMed/NCBI
8	Brunsvig PF, Kyte JA, Kersten C, et al: Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 17:6847–6857. 2011. View Article : Google Scholar : PubMed/NCBI
9	Joshi VG, Dighe VD, Thakuria D, et al: Multiple antigenic peptide (MAP): a synthetic peptide dendrimer for diagnostic, antiviral and vaccine strategies for emerging and re-emerging viral diseases. Indian J Virol. 24:312–320. 2013. View Article : Google Scholar :
10	Vlodavsky I, Ilan N, Naggi A and Casu B: Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparin sulfate. Curr Pharm Des. 13:2057–2073. 2007. View Article : Google Scholar
11	Vlodavsky I, Elkin M, Abboud-Jarrous G, et al: Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res. 49:207–210. 2008. View Article : Google Scholar : PubMed/NCBI
12	Roy M and Marchetti D: Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem. 106:200–209. 2009. View Article : Google Scholar :
13	Nasser NJ, Avivi A, Shafat I, et al: Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci USA. 106:2253–2258. 2009. View Article : Google Scholar : PubMed/NCBI
14	Vlodavsky I, Goldshmidt O, Zcharia E, et al: Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol. 12:121–129. 2002. View Article : Google Scholar : PubMed/NCBI
15	McKenzie EA: Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol. 151:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sommerfeldt N, Beckhove P, Ge Y, et al: Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res. 66:7716–7723. 2006. View Article : Google Scholar : PubMed/NCBI
17	Miao HQ, Liu H, Navarro E, et al: Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 13:2101–2111. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tang XD, Wan Y, Chen L, et al: H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo. Cancer Res. 68:1529–1537. 2008. View Article : Google Scholar : PubMed/NCBI
19	Liang XJ, Yuan L, Hu J, et al: Phosphomannopentaose sulfate (PI-88) suppresses angiogenesis by downregulating heparanase and vascular endothelial growth factor in an oxygen-induced retinal neovascularization animal model. Mol Vis. 18:1649–1657. 2012.PubMed/NCBI
20	Dredge K, Hammond E, Handley P, et al: PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 104:635–642. 2011. View Article : Google Scholar : PubMed/NCBI
21	He X, Brenchley PE, Jayson GC, et al: Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res. 64:3928–3933. 2004. View Article : Google Scholar : PubMed/NCBI
22	Borsig L, Vlodavsky I, Ishai-Michaeli R, et al: Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia. 13:445–452. 2011.PubMed/NCBI
23	Du L, Wang HJ, Yang JM, et al: T-helper epitope peptide improves immunological effects of the B cell epitopes of human heparanase protein. Chin J Microbiol Immunol. 28:869–872. 2008.
24	Yang JM, Wang HJ, Du L, et al: Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma. Cancer Immunol Immunother. 58:1387–1396. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liu X, Cai M, Wang X and Li X: One simple and efficient method for purification of IgG McAb from mice ascites: caprylic acid/ammonium sulfate precipitation. Hua Xi Yi Ke Da Xue Xue Bao. 30:455–456. 1999.(In Chinese).
26	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
27	Bridges JF, Dong L, Gallego G, et al: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. BMC Health Serv Res. 12:3762012. View Article : Google Scholar : PubMed/NCBI
28	Aravalli RN, Cressman EN, Steer CJ, et al: Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 87:227–247. 2013. View Article : Google Scholar
29	Darzynkiewicz Z: Will cancer immunotherapy fail? Scientist. 20:142006.
30	Kratky W, Reis e Sousa C, Oxenius A and Spörri R: Direct activation of antigen-presenting cells is required for CD8⁺ T-cell priming and tumor vaccination. Proc Natl Acad Sci USA. 108:17414–17419. 2011. View Article : Google Scholar
31	Koop A, Sellami N, Adam-Klages S, et al: Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal. 11:412013. View Article : Google Scholar : PubMed/NCBI
32	Weldon JE, Xiang L, Zhang J, et al: A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther. 12:48–57. 2013. View Article : Google Scholar :
33	Vonderheide RH: Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov Med. 7:103–108. 2007.PubMed/NCBI
34	Zhang YF, Tang XD, Gao JH, et al: Heparanase: a universal immunotherapeutic target in human cancers. Drug Discov Today. 16:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
35	Palena C and Schlom J: Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol. 2010:3806972010. View Article : Google Scholar : PubMed/NCBI
36	Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
37	Bonertz A, Weitz J, Pietsch DH, et al: Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest. 119:3311–3321. 2009.PubMed/NCBI
38	Ilan N, Elkin M, Vlodavsky I, et al: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018–2039. 2006. View Article : Google Scholar : PubMed/NCBI
39	Katz M, Lynn M, Solotorovsky M, et al: Serological and biological activities of anti-Haemophilus influenzae ribosomal serum. Infect Immun. 31:1125–1131. 1981.PubMed/NCBI
40	Levy-Adam F, Abboud-Jarrous G, Guerrini M, et al: Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem. 280:20457–20466. 2005. View Article : Google Scholar : PubMed/NCBI
41	Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
42	An FQ, Matsuda M, Fujii H and Matsumoto Y: Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol. 126:153–160. 2000. View Article : Google Scholar : PubMed/NCBI
43	Poon RT, Ng IO, Lau C, et al: Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 233:227–235. 2011. View Article : Google Scholar
44	Yang P, Yuan W, He J, et al: Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis. Hepatol Res. 39:1169–1177. 2009. View Article : Google Scholar : PubMed/NCBI
45	Xu YZ, Zhu Y, Shen ZJ, et al: Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine. 40:445–451. 2011. View Article : Google Scholar : PubMed/NCBI